Q2 2024 results - Thursday, July 18, 2024

Media release:
English (PDF 0.5 MB) | Deutsch (PDF 0.5 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.5 MB)


Watch the webcast

Download the podcast (MP3 34 MB)

Download the interactive presentation (PDF 5.5 MB)  

Read the transcript 
 

Key figures1

Continuing operations2

 Q2 2024
(USD m)
Q2 2023
(USD m)
% change
(USD/cc)
Net sales12,51211,4379 (cc: 11)
Operating income4,0142,80743 (cc: 47)
Net income3,2462,27143 (cc: 49)
EPS (USD)1.601.0947 (cc: 52)
Free cash flow4,6153,29240

Core
   
Operating income4,9534,24017 (cc: 19)
Net income4,0083,50214 (cc: 18)
EPS (USD)1.971.6917 (cc: 21)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 43 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 33 of the Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing corporate activities and Discontinued operations include operational results from the Sandoz business.

Q1 2024 results - Tuesday, April 23, 2024

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB)

Interim financial report (PDF 0.4 MB)


Watch the webcast

Download the podcast (MP3 30 MB)

Download the interactive presentation (PDF 6.0 MB)

Read the transcript

Novartis Q1 2024 impact and sustainability update (PDF 1.4 MB)
 

Key figures1

Continuing operations2

 Q1 2024
(USD m)
Q1 2023
(USD m)
% change
(USD/cc)
Net sales11,82910,79810 (cc: 11)
Operating income3,3732,61829 (cc: 39)
Net income2,6882,15025 (cc: 37)
EPS (USD)1.311.0228 (cc: 41)
Free cash flow2,0382,684-24

Core
   
Operating income4,5373,90616 (cc: 22)
Net income3,6813,23314 (cc: 19)
EPS (USD)1.801.5417 (cc: 23)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 34 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 26 of the Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

 

Annual results and Q4 2023
Wednesday, January 31, 2024

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)


Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)

Download 2023 epidemiology data (PDF 1.1 MB)
 

Key figures1

Continuing operations2

 Q4 2023
(USD m)
Q4 2022
(USD m)
% change
(USD/cc)
Net sales11,42310,5768 (cc: 10)
Operating income2,5821,75547 (cc: 68)
Net income2,6381,315101 (cc: 130)
EPS (USD)1.290.62108 (cc: 140)
Free cash flow2,1413,462-38

Core
   
Operating income3,8213,6455 (cc: 13)
Net income3,1262,9636 (cc: 11)
EPS (USD)1.531.3910 (cc: 16)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

Q3 2023 results - Tuesday, October 24, 2023

Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.6 MB)


Watch the webcast

Download the podcast (MP3 33 MB)

Download the presentation (PDF 3.5 MB)

Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)
 

Key figures1

Continuing operations2

 Q3 2023
(USD m)
Q3 2022
(USD m)
% change
(USD/cc)
Net sales11,78210,49212 (cc: 12)
Operating income1,7621,826-4 (cc: 13)
Net income1,5131,33014 (cc: 37)
EPS (USD)0.730.6120 (cc: 45)
Free cash flow5,0434,05424

Core
   
Operating income4,4053,77217 (cc: 21)
Net income3,5853,03518 (cc: 23)
EPS (USD)1.741.4024 (cc: 29)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

 

2023 quarterly results

Q2 2023 media release (PDF 0.3 MB)

Q2 2023 financial report (PDF 0.5 MB)

Q1 2023 media release (PDF 0.3 MB)

Q1 2023 financial report (PDF 0.3 MB)

2022 quarterly results

Q4 2022 media release (PDF 0.3 MB)

Q4 2022 financial report (PDF 0.5 MB)

Q3 2022 media release (PDF 0.3 MB)

Q3 2022 financial report (PDF 0.5 MB)

Q2 2022 media release (PDF 0.2 MB)

Q2 2022 financial report (PDF 0.5 MB)

Q1 2022 media release (PDF 0.2 MB)

Q1 2022 financial report (PDF 0.4 MB)

2021 quarterly results

Q4 2021 media release (PDF 0.3 MB)

Q4 2021 financial report (PDF 0.5 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

Q3 2021 media release (PDF 0.3 MB)

Q3 2021 financial report (PDF 0.5 MB)

Q2 2021 media release (PDF 0.4 MB)

Q2 2021 financial report (PDF 0.5 MB)

Q1 2021 media release (PDF 0.2 MB)

Q1 2021 financial report (PDF 0.4 MB)

2020 quarterly results

Q4 2020 media release (PDF 0.2 MB)

Q4 2020 financial report (PDF 0.9 MB)

Q3 2020 media release (PDF 0.2 MB)

Q3 2020 financial report (PDF 0.8 MB)

Q2 2020 media release (PDF 0.1 MB)

Q2 2020 financial report (PDF 0.8 MB)

Q1 2020 media release (PDF 0.2 MB)

Q1 2020 financial report (PDF 0.6 MB)

2019 quarterly results

Q4 2019 media release (PDF 0.1 MB)

Q4 2019 financial report (PDF 0.7 MB)

Q3 2019 media release (PDF 0.1 MB)

Q3 2019 financial report (PDF 0.8 MB)

Q2 2019 media release (PDF 0.2 MB)

Q2 2019 financial report (PDF 0.6 MB)

Q1 2019 media release (PDF 0.5 MB)

Q1 2019 financial report (PDF 0.5 MB)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.